This efficiency makes it viable for enterprises to move beyond generic off-the-shelf solutions and develop specialized models ...
Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale. Anti-BCMA antibody-drug conjugate (ADC) Blenrep (belantamab ...